AN OPEN-LABEL MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022 A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY

Brief description of study

CD19-directed autologous CAR T-cell therapy has changed the treatment landscape for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Nonetheless, up to 60% of patients undergoing autologous CD19-directed CAR T-cell therapy experience disease progression due to treatment resistance, including CD19-negative relapse; outcomes for these patients are poor. Therapy directed at an alternative B-cell-specific antigen may be able to overcome resistance to CD19-directed therapy. CRG-022 is an autologous CAR T-cell product targeting CD22, a common B-cell antigen widely expressed in LBCL. This study aims to evaluate the safety and the efficacy of CRG-022 in the treatment of participants with R/R LBCL that has progressed after CD19-directed CAR T-cell therapy, an area of high unmet need.


Clinical Study Identifier: s23-00080
ClinicalTrials.gov Identifier: NCT05972720
Principal Investigator: Catherine M Diefenbach.
Other Investigators: Chelsea F Curione, Jaime Andres Suarez Londono, Nicole Karich, Eileen Zhao, Maureen E Musatto, Jamie M Pavlonnis, David Kaminetzky, Kathryn Dowling, Marissa Hornacek, Kenneth B Hymes, Rafael C Singson, Amanda Marie Ferris, Tibor Moskovits, Oscar B Lahoud, Jingmei Hsu, Sejal Singh, Mohammad Maher Abdul Hay, Maxim Kreditor, Rena Kandinova, Shella Saint Fleur-Lominy, Kelsey Stocker, Ellaine R Yap, Laura P. Diaz, Michael L. Grossbard, Kristen Randolph Jordan, Bruce G Raphael, Jamie Robin Nemrow, Anna C Hatzinikolaou.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.